Abstract
Immunometabolism is a burgeoning field of research that investigates how immune cells harness nutrients to drive their growth and functions. Myeloid cells play a pivotal role in tumor biology, yet their metabolic influence on tumor growth and antitumor immune responses remains inadequately understood. This Review explores the metabolic landscape of tumor-associated macrophages, including the immunoregulatory roles of glucose, fatty acids, glutamine, and arginine, alongside the tools used to perturb their metabolism to promote antitumor immunity. The confounding role of metabolic inhibitors on our interpretation of myeloid metabolic phenotypes will also be discussed. A binary metabolic schema is currently used to describe macrophage immunological phenotypes, characterizing inflammatory M1 phenotypes, as supported by glycolysis, and immunosuppressive M2 phenotypes, as supported by oxidative phosphorylation. However, this classification likely underestimates the variety of states in vivo. Understanding these nuances will be critical when developing interventional metabolic strategies. Future research should focus on refining drug specificity and targeted delivery methods to maximize therapeutic efficacy.
Original language | English (US) |
---|---|
Article number | e175445 |
Journal | Journal of Clinical Investigation |
Volume | 134 |
Issue number | 2 |
DOIs | |
State | Published - Jan 16 2024 |
Funding
ABH serves on the advisory board of Caris Life Sciences and the WCG Oncology Advisory Board; receives royalty and milestone payments from DNAtrix for the licensing of patent no. 11,065,285; is supported by research grants from Celularity, Alnylam, and AbbVie, and receives consulting fees from Novocure and Istari Oncology. She additionally has active granted patents (no. 9,675,633, no. 9,399,662) and a patent pending (international applications PCT/US2022/019435 and US 63/158,642). Conflict of interest: ABH serves on the advisory board of Caris Life Sciences and the WCG Oncology Advisory Board; receives royalty and milestone payments from DNAtrix for the licensing of patent no. 11,065,285; is supported by research grants from Celularity, Alnylam, and AbbVie, and receives consulting fees from Novocure and Istari Oncology. She additionally has active granted patents (no. 9,675,633, no. 9,399,662) and a patent pending (international applications PCT/US2022/019435 and US 63/158,642). Copyright: © 2024, Dussold et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Reference information: J Clin Invest. 2024;134(2):e175445. https://doi.org/10.1172/JCI175445.
ASJC Scopus subject areas
- General Medicine